In the past few years remarkable progress has been made in curing hepatitis C (HCV). However, with the World Health Organization goal to eliminate HCV by 2030 looming, AASLD and EASL recognize there remain many challenges to elimination and are partnering to produce a special conference aimed at determining the next steps.
Registration is open for AASLD/EASL HCV Special Conference on Feb. 1-2 in Miami, Fla.
“It’s an opportunity to share intelligence from practitioners of elimination worldwide, and for us to understand what it will take to get to the promised land from a practical management standpoint,” said. Raymond T. Chung, MD, FAASLD, one of four program co-chairs. “It’s an opportunity for people to get their heads together and chart a course forward.”
Co-chair David L. Thomas, MD, added that the event is bringing some of the pioneers in HCV research to Miami, including Harvey Alter, MD, FAASLD, best known for his work that led to the discovery of HCV and elimination of it from the blood supply, who will open and close the program.
“We’ll be reflecting on those successes, but then we pivoted to asking people to address the unmet needs, and those principally have to do with the global perspective of how to eliminate HCV around the world,” said Dr. Thomas.
The program is divided into six sessions over two days and will include not only the current research and treatment successes from around the world, but also significant time for attendees to consider unmet needs in HCV and begin to formulate a plan toward elimination.
“We’re going to learn from the successes of various models of cure that have been implemented in a variety of different corners of the world. We’re going to look at the success in microelimination strategies used in Europe where several countries have made real progress toward achieving WHO targets,” said Dr. Chung.
Dr. Thomas noted that anyone who is interested in the state of the art in HCV and future plans in disease treatment and elimination should attend.
“AASLD and EASL share a commitment to discovery when it comes to hepatitis and to public health improvements of hepatitis outcomes, and so we’re partnering together to bring all the smartest people in the room and brainstorm on what we know and what we need to know and what we need to do,” said Dr. Thomas.
Markus Cornberg, MD, and Alessio M. Aghemo, MD, PhD, are also serving as program co-chairs.
For more information about the program or to register, click here.